Develops a therapeutic technology platform that improves immune system recognition and response to tissues, malignancies, and pathogens. This approach targets autoimmune diseases and cancer, aiming to enhance treatment efficacy and patient outcomes by enabling the immune system to better identify and combat these conditions.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IGFounders
Product
Problem
Current immunotherapies often struggle with limited efficacy due to the immune system's inability to effectively recognize and target specific tissues, malignancies, or pathogens. This lack of precise recognition can lead to suboptimal treatment responses and reduced patient outcomes in autoimmune diseases and cancer.
Solution
Resseptor Therapeutics is developing a therapeutic technology platform designed to enhance the immune system's ability to recognize and respond to tissues, malignancies, and pathogens. Their approach aims to improve the precision and effectiveness of immunotherapies, leading to better treatment outcomes for patients with autoimmune diseases and cancer. By enhancing immune system recognition, Resseptor's platform seeks to overcome the limitations of existing therapies and unlock the full potential of the body's natural defenses.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel immunotherapies for autoimmune diseases and cancer.
Features
- Technology platform designed to improve immune system recognition of target tissues.
- Focus on enhancing immune responses in autoimmune diseases and cancer.
- Aims to increase the efficacy of existing immunotherapies.